- Home
- ESLA vs RAND Comparison
ESLA vs RAND Comparison
Compare ESLA & RAND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ESLA
- RAND
- Stock Information
- Founded
- ESLA 2021
- RAND 1969
- Country
- ESLA United States
- RAND United States
- Employees
- ESLA N/A
- RAND N/A
- Industry
- ESLA Biotechnology: Biological Products (No Diagnostic Substances)
- RAND Finance: Consumer Services
- Sector
- ESLA Health Care
- RAND Finance
- Exchange
- ESLA Nasdaq
- RAND Nasdaq
- Market Cap
- ESLA 41.6M
- RAND 47.5M
- IPO Year
- ESLA N/A
- RAND N/A
- Fundamental
- Price
- ESLA $0.91
- RAND $16.33
- Analyst Decision
- ESLA
- RAND
- Analyst Count
- ESLA 0
- RAND 0
- Target Price
- ESLA N/A
- RAND N/A
- AVG Volume (30 Days)
- ESLA 16.9K
- RAND 2.4K
- Earning Date
- ESLA 11-14-2024
- RAND 11-06-2024
- Dividend Yield
- ESLA N/A
- RAND 7.10%
- EPS Growth
- ESLA N/A
- RAND 123.39
- EPS
- ESLA N/A
- RAND 4.98
- Revenue
- ESLA N/A
- RAND $8,351,941.00
- Revenue This Year
- ESLA N/A
- RAND N/A
- Revenue Next Year
- ESLA N/A
- RAND N/A
- P/E Ratio
- ESLA N/A
- RAND $3.28
- Revenue Growth
- ESLA N/A
- RAND 16.96
- 52 Week Low
- ESLA $0.63
- RAND $12.50
- 52 Week High
- ESLA $3.23
- RAND $19.60
- Technical
- Relative Strength Index (RSI)
- ESLA 53.92
- RAND 48.83
- Support Level
- ESLA $0.74
- RAND $16.05
- Resistance Level
- ESLA $0.99
- RAND $16.46
- Average True Range (ATR)
- ESLA 0.09
- RAND 0.13
- MACD
- ESLA 0.02
- RAND 0.04
- Stochastic Oscillator
- ESLA 72.88
- RAND 63.11
About ESLA Estrella Immunopharma Inc.
Estrella Immunopharma Inc is a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS T-cell therapies with the capacity to address treatment challenges for patients with blood cancers and solid tumors. Estrella's mission is to harness the evolutionary power of the human immune system to transform the lives of patients fighting cancer and autoimmune diseases.
About RAND Rand Capital Corporation
Rand Capital Corp is a closed-end, diversified management company. The firm's investment objectives is to maximize the total return to the shareholders with current income combined with capital appreciation. Some of its portfolios include lumious, and GiveGab among others.